ALK B ALK-ABELLO A/S

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende medarbejderes transaktioner som beskrevet i vedhæftede meddelelse.

ALK-Abelló A/S

For yderligere oplysninger kontakt venligst:

Investor Relations: Per Plotnikof, mobil 2261 2525

Presse: Jeppe Ilkjær, mobil 3050 2014

Vedhæftet fil



EN
25/08/2022

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ITULATEK® approved for treatment of children and adolescents in Canada

ITULATEK® approved for treatment of children and adolescents in Canada ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, hazel, and/or oak, in children, adolescents, and adults five to 65 years of age in Canada. Outside Europe, Can...

May 8, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
05/08/25 May 8, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
05/06/25 May 6, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Three-month interim report (Q1) 2025 (unaudited) - English version onl...

Three-month interim report (Q1) 2025 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på  engelsk. ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free cash flow almost tripled. Outlook remains unchanged. Performance highlights Comparative figures for Q1 2024 are shown in brackets. Growth rates are ...

May 6, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Three-month interim report (Q1) 2025 (unaudited)

Three-month interim report (Q1) 2025 (unaudited) ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free cash flow almost tripled. Outlook remains unchanged. Performance highlights Comparative figures for Q1 2024 are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated. Total revenue increased by 12% to ...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch